GlassScriptPhysician profile
James A Dean
NPI 1649581752
$9,856.23
in general payments reported to CMS, 2019-2025
31 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $482 · 2021: $973 · 2022: $1,697 · 2023: $4,004 · 2024: $890 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,825.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,016.99 | 2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $2,032.78 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,667.67 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,110.27 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $502.39 | 2020-2025 | Cuvitru, Glassia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $273.50 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $195.73 | 2020-2023 | Xolair |
| Genzyme Corporation | $141.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $111.46 | 2019-2022 | |
| Electromed, INC. | $79.29 | 2019-2024 | Smartvest |
| Mylan Specialty L.P. | $72.59 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $52.99 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $51.06 | 2019-2020 | |
| Philips North America LLC | $50.16 | 2019 | |
| United Therapeutics Corporation | $46.55 | 2021-2025 | Tyvaso |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $41.60 | 2019 | |
| Viatris Specialty LLC | $40.80 | 2025 | Yupelri |
| Pulmonx Corporation | $38.34 | 2022-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Pfizer INC. | $36.55 | 2023-2024 | |
| Shire North American Group INC | $34.84 | 2019 | |
| Baxter Healthcare | $31.59 | 2022 | |
| Mallinckrodt Hospital Products INC. | $27.42 | 2024 | Acthar |
| Inogen, INC. | $27.26 | 2022-2024 | |
| Chiesi USA, INC. | $26.91 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.42 | 2024 | Purified Cortrophin Gel |
| Ethicon INC. | $23.60 | 2022 | |
| Octapharma USA, INC. | $23.49 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.87 | 2022 | |
| Amgen INC. | $19.96 | 2022 | |
| Kaleo, INC. | $18.75 | 2023 | Auvi-Q |
| Janssen Pharmaceuticals, INC | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.